News Archive

Jun 14 2024, 12:00
Oren Moscovitz Wins Prestigious Hermann Neuhaus Prize

Dr. Oren Moscovitz has been awarded €25,000 by the Max Planck Society for his promising research toward treatments and non-invasive diagnostics for cancer, which could potentially reduce overall cancer-related deaths. Moscovitz and his team exploit unique sugar patterns found on cancer cells and develop ultra-small antibodies from alpacas (known as nanobodies) that bind to these sugars.

 

https://www.mpikg.mpg.de/6834320/hermannneuhaus-prize-for-moscovitz?c=132305

Download document
Jun 11 2024, 13:34
Tacalyx extends seed round to €14M

 

Read the full press release here:

Download document
Apr 08 2024, 18:00
TCX-101

TCX-101, a novel antibody-drug conjugate targeting a tumor- associated carbohydrate antigen for the treatment of solid tumors

Download document
Mar 28 2024, 18:00
Tacalyx to present at AACR 2024

TCX-101, a novel antibody-drug conjugate targeting a tumor-associated carbohydrate antigen for the treatment of solid tumors

F. G. Gomes, F. Muraca, G. M. Schmidt Garcia Moreira, K. Rösch, M. Bräutigam, P. Sondermann, M. Ocker

Monday, 8th April, 1:30 - 5:00 PM (PST)
Session PO.ET02.01 - Antibody Drug Conjugates (Section 21)
Poster 3125/ 6

Mar 15 2024, 18:00
AACR Annual Meeting 2024 in San Diego

"This event is a fantastic opportunity for us to showcase our latest advancements and explore partnerships to further elevate our cancer research."

MATTHIAS OCKER Head of Experimental Medicine at Tacalyx

Jun 05 2023, 12:00
Tacalyx and Leiden University Medical Center join forces to target tumor specific glycans in colorectal cancer

€ 500 K Health~Holland grant for new initiative against colorectal cancer. Read the full press release here:

Download document
Nov 05 2020, 12:00
Tacalyx Appoints Dr. Klaus Schollmeier as Chairman of the Board

Senior Pharma/Biotech and Life Science Expert joins Tacalyx´s Board of Directors as Chairman. Read the full press release here:

Download document
Sep 25 2019, 14:00
Tacalyx Raises €7 Million in Seed Funding to Generate First in Class Anti-TACA Antibodies for Cancer Treatment

Read the full press release here:

Download document
Tacalyx GmbH

Magnusstr. 11
12489 Berlin
Germany

Follow Us